Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- VYNE Therapeutics Inc (NASDAQ:VYNE) announced positive efficacy results from the Phase 1b segment of Phase 1b/2a trial of FMX114 in mild-to-moderate atopic dermatitis (AD).
- Mean Atopic Dermatitis Severity Index (ADSI) scores for FMX114 and vehicle-treated lesions were 7.8 and 8.0, respectively, at baseline.
- The mean reduction in ADSI score from baseline was -6.3 (-81.4% mean reduction) for FMX114 treated lesions compared to -4.3 (-54.3% mean reduction) for vehicle-treated lesions at week 2.
- Also Read: VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis.
- Subjects reported a 96.4% mean reduction in worst pruritus (itch) from baseline for lesions treated with FMX114 compared to a 45.8% mean reduction for vehicle-treated lesions at week 2.
- The Company expects topline results from the Phase 2a segment of the study in Q2 of 2022.
- FMX114 is VYNE's proprietary investigational combination gel formulation of tofacitinib and fingolimod.
- Price Action: VYNE shares are up 5.82% at $0.65 during the market session on the last check Thursday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!